Product nameAnti-Cyclin D1 (phospho T286) antibody
See all Cyclin D1 primary antibodies
DescriptionRabbit polyclonal to Cyclin D1 (phospho T286)
SpecificityDetects endogenous levels of Cyclin D1 only when phosphorylated at threonine 286
Tested applicationsSuitable for: WB, ELISAmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse
Synthetic phosphopeptide derived from human Cyclin D1 around the phosphorylation site of threonine 286 (A-C-TP-P-T).
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Concentration information loading...
PurityImmunogen affinity purified
Purification notesPurified from rabbit antiserum by affinity chromatography using epitope specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Our Abpromise guarantee covers the use of ab62151 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/2000. Detects a band of approximately 31 kDa (predicted molecular weight: 33 kDa).|
FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
modificationsPhosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
- Information by UniProt
- AI327039 antibody
- B cell CLL/lymphoma 1 antibody
- B cell leukemia 1 antibody
All lanes : Anti-Cyclin D1 (phospho T286) antibody (ab62151) at 1/500 dilution
Lane 1 : Extracts from Jurkat cells treated with EGF (200ng/ml, 30mins)
Lane 2 : Extracts from Jurkat cells treated with EGF (200ng/ml, 30mins) with immunizing phosphopeptide
Predicted band size: 33 kDa
Observed band size: 31 kDa why is the actual band size different from the predicted?
This product has been referenced in:
- Chen H et al. CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells. J Biol Chem 292:10131-10141 (2017). Read more (PubMed: 28446612) »
- Sun X et al. Let-7: a regulator of the ERa signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep 29:2079-87 (2013). Read more (PubMed: 23467929) »